Trial Profile
An Open Label Phase II Study on the efficacy of Nivolumab(ONO-4538) in Japanese Subjects with cancer of unknown primary (CUP) (NivoCUP)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Cancer; Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NivoCUP
- 26 Nov 2021 Primary endpoint (Overall response rate) has been met as per results published in the Annals of Oncology
- 26 Nov 2021 Results published in the Annals of Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology